Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2015

View Archived Issues

Athersys and Chugai sign Japanese agreement for MultiStem in ischemic stroke

FDA approves Liletta to prevent pregnancy for up to three years

GSK/Novartis transaction complete

Cardinal Health offers to acquire Cordis from Johnson & Johnson

FDA grants breakthrough therapy designation to Epstein-Barr virus targeted T cells

SBIR supports collaborative work in brain cancer between Nascent Biotech and Mapp Biopharmaceutical

Multiplatform tumor profiling shows potential for therapeutic decision-making

Dilafor releases results from safety and pharmacokinetic study of tafoxiparin

Anticoagulant-reversing agent andexanet alfa given FDA orphan drug status

Alkermes highlights new drug candidate, ALKS-7119

Alize Pharma begins phase II trial of AZP-531 in Prader-Willi syndrome

Lupin patents CaSR modulators

Constellation Pharmaceuticals reports development of EZH2 inhibitors

British investigators prepare new oligomers for muscular dystrophy

Resilience and PsychoGenics form drug discovery partnership

Celimmune enters into licensing and option agreement with Amgen to develop AMG-714

Mast Therapeutics reports data from nonclinical study of vepoloxamer in advanced heart failure

Clearside Biomedical begins phase II trial of CLS-TA in macular edema

FIOCRUZ patents new compounds for respiratory inflammatory diseases

Merck KGaA reports new tankyrase inhibitors

Denovo Biopharma licenses Lilly's pomaglumetad methionil

Pulmokine secures funding for phase I trial of PDGF receptor kinase inhibitor PK-10571

Prevenar 13 approved in E.U. for prevention of pneumococcal pneumonia in adults

Novel means of blocking Ebola entry into cells with existing agents identified

PSMA antibody-drug conjugate shows potential for the treatment of prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...